Our two clinical-stage product candidates each target a key mechanism that inhibits an effective antitumor response. With the novel checkpoint TIGIT, we are advancing belrestotug. For ENT1, a target in the ATP adenosine pathway, we are advancing EOS-984. We believe that each product candidate has the potential to further increase patient responses to standard cancer therapies, including immunotherapy. We are evaluating numerous biomarkers in our clinical programs to maximize this potential through choosing synergistic combination agents and identifying patients most likely to benefit from our product candidates.

We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.